Ligand to Participate in Upcoming Investor Conferences

Ligand to Participate in Upcoming Investor Conferences




Ligand to Participate in Upcoming Investor Conferences

JUPITER, Fla.–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Todd Davis (Chief Executive Officer) and Tavo Espinoza (Chief Financial Officer) will participate in the following upcoming investor conferences:


  • Craig-Hallum Institutional Investor Conference (Minneapolis). Management will participate in one-on-one meetings on May 29, 2024.
  • Goldman Sachs Global Healthcare Conference (Miami). Management will present on June 12, 2024 at 4:00 p.m. ET.

Management is scheduled to host one-on-one meetings with investors and attendees during both of these conferences. Investors interested in arranging one-on-one meetings should contact their Craig-Hallum and / or Goldman Sachs institutional equity sales representative.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Its business model seeks to generate value for stockholders by creating a diversified portfolio of biopharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand’s goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Its business model focuses on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing its technology to help partners discover and develop medicines. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate its revenue. Ligand’s Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading biopharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X @Ligand_LGND.

We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.

Contacts

For Ligand:
Investors:
Michael Jeong

investors@ligand.com
(561) 214-4232

LifeSci Advisors

Bob Yedid

bob@lifesciadvisors.com
(516) 428-8577

Media:

Kellie Walsh

media@ligand.com
(914) 315-6072